Search
Arsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalThe enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Roxithromycin
go.drugbank.com/drugs/DB00778ApprovedInvestigationalWithdrawnIt is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. … It was shown to be more effective against certain Gram-negative bacteria, particularly _Legionella pneumophila_.
International brands: CoroxinProducts: COROXIN 300 MG TABLETTiopronin
go.drugbank.com/drugs/DB06823ApprovedAs cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. … It has been investigated for use in the treatment of arthritis and as a neuroprotective agent in aneurysmal subarachnoid hemorrhage.
Insulin beef
go.drugbank.com/drugs/DB09456ApprovedInsulin beef has been discontinued in the US and Canada since 2017.[L10827]
Oxatomide
go.drugbank.com/drugs/DB12877ApprovedOxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.
Parthenolide
go.drugbank.com/drugs/DB13063ApprovedInvestigationalParthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Butaperazine
go.drugbank.com/drugs/DB13213ApprovedButaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].
Elacytarabine
go.drugbank.com/drugs/DB05494InvestigationalCytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. … Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells.
Dalfopristin
go.drugbank.com/drugs/DB01764ApprovedDalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Da...
Tienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnTienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. … It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982)